Research Article

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia

Table 1

Baseline characteristics of the study participants.

CharacteristicsLAI antipsychotic monotherapy group ()Combination of LAI and oral antipsychotics group ()

Median (IQR)
Age, years34.0 (27.0, 47.0)34.0 (27.0, 41.0)
Body weight, kg59.2 (50.5, 69.5)61.2 (56.3, 70.8)
Body mass index, kg/m223.9 (21.2, 25.0)24.0 (22.4, 24.3)
Age at onset of illness, years32.0 (22.8, 41.5)30.0 (22.2, 35.0)
Duration of illness, years3.0 (1.0, 4.5)2.0 (0.5, 7.5)
Dose of LAI antipsychotic, mg (flupenthixol decanoate equivalent)33.0 (20.0, 63.5)40.0 (20.0, 50.0)
Dose of oral antipsychotic, mg (chlorpromazine equivalent)0.0 (0.0, 0.0)333.0 (200.0, 600.0)
(%)
Sex (% male)10 (40.0)34 (55.7)
Marital status, % single16 (64.0)47 (77.0)
Psychiatric comorbidities, (%)
 Bipolar disorder05 (8.2)
 Major depressive disorder1 (4.0)2 (3.3)
 Catatonia01 (1.6)
Comedications, (%)
 Anti-EPS20 (80.0)53 (86.9)
 Sedatives/anxiolytics13 (52.0)30 (49.2)
 Mood stabilizers2 (8.0)5 (8.2)
 Antidepressants1 (4.0)6 (9.8)
Substances, (%)
 Alcohol6 (24.0)16 (26.2)
 Amphetamine4 (16.0)5 (8.2)
 Cannabis03 (4.9)
 Tobacco5 (20.0)26 (42.6)
 Others1 (4.0)1 (1.6)
LAI antipsychotics
 Fluphenazine decanoate2 (8.0)11 (18.0)
 Flupentixol decanoate14 (56.0)30 (49.2)
 Haloperidol decanoate6 (24.0)12 (19.7)
 Paliperidone palmitate3 (12.0)4 (6.6)
 Risperidone0 (0.0)4 (6.6)

EPS: extrapyramidal side effect; LAI: long-acting injectable. .